Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain.

One of the major binding sites for factor VIII inhibitors is located within the A2 domain. In this study, phage display technology was used to isolate 2 human monoclonal antibodies, termed VK34 and VK41, directed toward the heavy chain of factor VIII. The V(H) domain of a single-chain variable domain antibody fragment (scFv) VK34 is encoded by germline gene segment DP-10. Epitope-mapping studies revealed that scFv VK34 is directed against amino acid residues Arg(484)-Ile(508), a previously identified binding site for factor VIII inhibitors in the A2 domain. ScFv VK34 inhibited factor VIII activity with a titer of 280 BU/mg. The V(H) domain of VK41 was encoded by germline gene segment DP-47. A phage corresponding to VK41 competed with a monoclonal antibody for binding to amino acid residues Asp(712)-Ala(736) in the acidic region adjacent to the A2 domain. Reactivity of VK41 with a factor VIII variant in which we replaced amino acid residues Asp(712)-Ala(736) for the corresponding region of heparin cofactor II was strongly reduced. In addition, substitution of Tyr(718719723) for Phe abrogated binding of VK41 to factor VIII. ScFv VK41 did not inhibit factor VIII activity. This study not only defines the primary structure of human anti-factor VIII antibodies reactive with the A2 domain, it also describes an antibody with an epitope not previously identified in the antibody repertoire of hemophilia patients with an inhibitor. (Blood. 2000;96:540-545)

[1]  J. Healey,et al.  Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. , 2000, Blood.

[2]  W. Ouwehand,et al.  Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. , 2000, Blood.

[3]  P. Fay,et al.  Human Inhibitor Antibodies Specific for the Factor VIII A2 Domain Disrupt the Interaction between the Subunit and Factor IXa* , 1999, The Journal of Biological Chemistry.

[4]  J. Voorberg,et al.  Longitudinal Analysis of Factor VIII Inhibitors in a Previously Untreated Mild Haemophilia A Patient with an Arg593→Cys Substitution , 1999, Thrombosis and Haemostasis.

[5]  R M Hoet,et al.  Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire. , 1999, Journal of molecular biology.

[6]  P. Lenting,et al.  The life cycle of coagulation factor VIII in view of its structure and function. , 1998, Blood.

[7]  J. Healey,et al.  Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. , 1998, Blood.

[8]  M. Shima,et al.  Some human inhibitor antibodies interfere with factor VIII binding to factor IX. , 1998, Blood.

[9]  J. T. ten Cate,et al.  A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. , 1998, Blood.

[10]  J. Healey,et al.  Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis* , 1997, The Journal of Biological Chemistry.

[11]  J. T. ten Cate,et al.  The missense mutation Arg593 --> Cys is related to antibody formation in a patient with mild hemophilia A. , 1997, Blood.

[12]  I. Scharrer,et al.  The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. , 1997, Blood.

[13]  J. V. van Mourik,et al.  Enhanced Thrombin Sensitivity of a Factor VIII-Heparin Cofactor II Hybrid* , 1996, The Journal of Biological Chemistry.

[14]  P. Lenting,et al.  The Sequence GluLys of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX (*) , 1996, The Journal of Biological Chemistry.

[15]  W. Ouwehand,et al.  A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library. , 1995, Blood.

[16]  G. E. Gilbert,et al.  Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. , 1995, Blood.

[17]  J. Healey,et al.  Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII (*) , 1995, The Journal of Biological Chemistry.

[18]  J. Huston,et al.  In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. , 1995, Immunotechnology : an international journal of immunological engineering.

[19]  P. T. Jones,et al.  Isolation of high affinity human antibodies directly from large synthetic repertoires. , 1994, The EMBO journal.

[20]  J. E. Curtis,et al.  Inhibition of human factor VIIIa by anti-A2 subunit antibodies. , 1994, The Journal of clinical investigation.

[21]  P. Lenting,et al.  Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. , 1994, The Journal of biological chemistry.

[22]  M. Verbeet,et al.  Biological activity of recombinant factor VIII variants lacking the central B‐domain and the heavy‐chain sequence Lys713‐Arg740: discordant in vitro and in vivo activity , 1993, British journal of haematology.

[23]  T. T. Wu,et al.  Length distribution of CDRH3 in antibodies , 1993, Proteins.

[24]  M. Shima,et al.  A Factor VIII Neutralizing Monoclonal Antibody and a Human Inhibitor Alloantibody Recognizing Epitopes in the C2 Domain Inhibit Factor VIII Binding to von Willebrand Factor and to Phosphatidylserine , 1993, Thrombosis and Haemostasis.

[25]  J. H. Wang,et al.  Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII. , 1992, Biochemistry.

[26]  H R Hoogenboom,et al.  By-passing immunization. Human antibodies from V-gene libraries displayed on phage. , 1991, Journal of molecular biology.

[27]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[28]  L. Hoyer,et al.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. , 1989, The Journal of clinical investigation.

[29]  R. Houghten,et al.  Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. , 1988, The Journal of clinical investigation.

[30]  L. Hoyer.  Medical progress : hemophilia A , 1994 .

[31]  D. Green,et al.  A More Uniform Measurement of Factor VIII Inhibitors , 1975, Thrombosis and Haemostasis.

[32]  J. Veltkamp,et al.  Detection of the Carrier State in Hereditary Coagulation Disorders II , 1968, Thrombosis and Haemostasis.